Akoya Biosciences, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
DEFM14A: Quanterix and Akoya Biosciences Announce Amended Merger Agreement and Shareholder Vote Details
Quanterix Corporation and Akoya Biosciences, Inc. have announced an amended merger agreement, where Akoya shareholders will receive a mix of Quanterix stock and cash, aiming to create a fully integrated technology ecosystem for biomarker detection.
Quanterix Corporation will acquire Akoya Biosciences, Inc. in an all-stock transaction, pending stockholder and regulatory approvals.
Akoya Biosciences announces its 2024 Annual Meeting of Stockholders to be held on June 4, 2024, featuring the election of directors and ratification of the company's accounting firm.
Akoya Biosciences announces its 2024 Annual Meeting of Stockholders to be held on June 4, 2024, featuring proposals for director elections and ratification of the company's accounting firm.